Abele Michael, Bajčiová Viera, Wright Fiona, Behjati Sam, Voggel Sarah, Schneider Dominik T, Mallebranche Coralie, Česen Mazič Maja, Guillén Gabriela, Krawczyk Malgorzata, Bień Ewa, Roganovic Jelena, Bisogno Gianni, Chiaravalli Stefano, Ferrari Andrea, Brecht Ines B, Orbach Daniel, Reguerre Yves, Virgone Calogero
Pediatric Hematology/Oncology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany.
Department of Pediatric Oncology, Childrens University Hospital, Brno, Czech Republic.
Eur J Cancer. 2022 Nov;175:19-30. doi: 10.1016/j.ejca.2022.08.007. Epub 2022 Sep 7.
Primary lung carcinoma is an exceptionally rare childhood tumour, as per definition of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT), with an incidence of 0.1-0.2/1,000,000 per year. Little is known about the clinical characteristics of children with primary lung carcinoma, a gap which this joint analysis of the EXPeRT group aimed to fill.
We performed a retrospective case series of children (aged 0-18 years) with primary lung carcinoma, as collected through the EXPeRT databases between 2000 and 2021. We recorded relevant clinical characteristics including treatment and outcome.
Thirty-eight patients were identified with a median age of 12.8 years at diagnosis (range: 0-17). Mucoepidermoid carcinoma (MEC) was the most frequent entity (n = 20), followed by adenocarcinoma (n = 12), squamous cell carcinoma (n = 4), adenosquamous carcinoma (n = 1) and small-cell lung cancer (n = 1). Patients with MEC presented rarely with lymph node metastases (2/20 cases). Overall, 19/20 patients achieved long-lasting remission by surgical resection only. Patients with other histologies often presented in advanced stages (14/18 TNM stage IV). With multimodal treatment, 3-year overall survival was 52% ± 13%. While all patients with squamous cell carcinoma died, the 12 patients with adenocarcinoma had a 3-year overall survival of 64% ± 15%.
Primary lung carcinomas rarely occur in children. While the outcome of children with MEC is favourable with surgery alone, patients with other histotypes have a poor prognosis, despite aggressive treatment, highlighting the need to develop new strategies for these children, such as mutation-guided treatment.
根据欧洲儿科罕见肿瘤合作研究组(EXPeRT)的定义,原发性肺癌是一种极其罕见的儿童肿瘤,每年发病率为0.1 - 0.2/1,000,000。关于原发性肺癌患儿的临床特征知之甚少,EXPeRT组的这项联合分析旨在填补这一空白。
我们对2000年至2021年间通过EXPeRT数据库收集的原发性肺癌患儿(0至18岁)进行了回顾性病例系列研究。我们记录了相关临床特征,包括治疗情况和结局。
共确定了38例患者,诊断时的中位年龄为12.8岁(范围:0至17岁)。黏液表皮样癌(MEC)是最常见的类型(n = 20),其次是腺癌(n = 12)、鳞状细胞癌(n = 4)、腺鳞癌(n = 1)和小细胞肺癌(n = 1)。MEC患者很少出现淋巴结转移(2/20例)。总体而言,19/20例患者仅通过手术切除就实现了长期缓解。其他组织学类型的患者常处于晚期(14/18例为TNM IV期)。采用多模式治疗,3年总生存率为52%±13%。虽然所有鳞状细胞癌患者均死亡,但12例腺癌患者的3年总生存率为64%±15%。
原发性肺癌在儿童中很少见。虽然MEC患儿单纯手术的预后良好,但其他组织学类型的患者尽管接受了积极治疗,预后仍很差,这凸显了为这些患儿制定新策略的必要性,如基于突变的治疗。